Private Advisor Group, LLC Editas Medicine, Inc. Transaction History

Private Advisor Group, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$26.55 - $40.57 $167,158 - $255,428	-6,296 Closed	0 $0
Q3 2021 Oct 14, 2021	SELL	$39.27 - $72.94 $203,693 - $378,339	-5,187 Reduced 45.17%	6,296 $259,000
Q2 2021 Aug 12, 2021	SELL	$31.29 - $56.64 $30,351 - $54,940	-970 Reduced 7.79%	11,483 $650,000
Q1 2021 Apr 22, 2021	BUY	$39.71 - $90.58 $186,319 - $425,001	4,692 Added 60.46%	12,453 $523,000
Q4 2020 Apr 01, 2021	BUY	$27.07 - $84.35 $210,090 - $654,640	7,761 New	7,761 $545,000
Q3 2020 Nov 02, 2020	SELL	$28.06 - $37.16 $123,155 - $163,095	-4,389 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$18.5 - $34.34 $81,196 - $150,718	4,389 New	4,389 $130,000

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Private Advisor Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Private Advisor Group, LLC with notifications on news.